CA-ALORICA-INC
24.1.2023 10:16:39 CET | Business Wire | Press release
Alorica Inc., a trusted leader in next-generation customer experience (CX) solutions, today announced its expansion plans into Africa and Europe through the launch of its operations in Cairo, Egypt and Łódź, Poland. As one of the largest business process outsourcers (BPO) globally with 100,000 employees across 17 countries and 24 years of CX experience—Alorica continues to scale and diversify its best-in-class workforce, now with a presence in these new markets. Setting up operations in Egypt and Poland further enables the digital CX company to meet the growing expectations of multinational companies to deliver industry-leading business outcomes including multilingual customer care, revenue generation, content management & content moderation, tech support and CX consulting. Alorica plans to open for business in both countries during second quarter of this year.
“Growth through Africa and Europe is key to our strategy of offering culturally and linguistically relevant support to well-established and emerging businesses worldwide,” said Greg Haller, Chief Executive Officer at Alorica. “Egypt and Poland have been on our radar as robust commercial markets with a strong talent pipeline. Our new operations will unlock career opportunities for local residents and create a distinct path to extend our solutions to clients in the region.”
With the expansion into Egypt and Poland, Alorica continues its investment into high-growth markets with scalable talent. Its experienced workforce offers CX support in over 30 languages to service brands in high-demand industries ranging from financial services, technology, travel & hospitality to e-commerce and retail among others. With existing operations of 1,000+ employees in Sofia, Bulgaria, the company will continue to leverage its innovative technologies to engage employees and customers through a combination of its work-at-home and on-site programs.
In Cairo, Alorica’s new contact center is strategically located in Sheikh Zayed City near top private universities, while its site in Łódź, Poland is in the heart of the city near Warsaw—accessible to high-caliber candidates. Both locations are equipped with numerous onsite amenities—accessible transportation, public services, retail stores, and more—while providing maximum efficiency for both brick-and-mortar and work-at-home operations that appeals to a multicultural and multilingual workforce.
Rooted in a people-first foundation, Alorica focuses on employee engagement as a critical driver of performance. The company prides itself on its socially responsible and inclusive work environment, which has resulted in record high employee satisfaction scores. A pioneer in versatile operating models that fosters flexibility, Alorica offers jobs around the globe across state-of the-art contact centers as well as through its work-at-home solution Alorica Anywhere and hybrid Connection Hubs—serving as important channels to link teams for collaboration, training and continuous improvement.
“Leveraging Alorica’s global scale and deep experience, we will provide localized service delivery to companies here in the region, while also enhancing EMEA’s reputation as the top outsourcing destination for customers everywhere,” said Alorica’s EMEA President Matt Sims. “I’m excited to bring Alorica’s mission-driven culture to Egypt and Poland as we hire and develop talented individuals from diverse backgrounds who are passionate about making lives better. As part of our corporate social responsibility, we are committed to not only doing business in the region, but also making an impact through our philanthropic work, people-focused programs and sustainability initiatives, benefiting the communities where our employees live and work. We’re looking forward to creating many jobs in these countries.”
The company continues to receive industry honors for its world-class vision and operational excellence—having been named a Leader in the 2022 Gartner Magic Quadrant for Customer Service BPO for the second consecutive year. Alorica has also garnered recognition as an employer of choice for its purposeful culture and employee engagement, winning awards such as Top Places to Work, Employer of the Year and Best in Biz, while also earning Great Place to Work® certifications for its operations in the Philippines and Guatemala.
To learn more about Alorica’s insanely great CX services in EMEA, email us at info@alorica.com.
About Alorica
Alorica creates insanely great digital customer experiences at scale. Our team of 100,000 solutionists, technologists and operators partner with global brands and disruptive innovators to deliver digitally-charged, tailored interactions customers crave. With a track record of creating long-term loyalty, Alorica brings actionable insights, proven processes and CX leadership to transform clients’ business needs, whether they’re focused on digital optimization, customer engagement or market expansion. Through strategic partnerships with best-in-breed technology, we design, integrate and optimize digital solutions personalized to reach clients’ most desired outcomes now and for the future. Alorica drives CX innovation for the best clients around the globe from its award-winning operations in 17 countries worldwide. To learn more, visit www.alorica.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
